BRPI0411112A - proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga - Google Patents

proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga

Info

Publication number
BRPI0411112A
BRPI0411112A BRPI0411112-5A BRPI0411112A BRPI0411112A BR PI0411112 A BRPI0411112 A BR PI0411112A BR PI0411112 A BRPI0411112 A BR PI0411112A BR PI0411112 A BRPI0411112 A BR PI0411112A
Authority
BR
Brazil
Prior art keywords
fusion protein
heterologous fusion
treating
polynucleotide
vector
Prior art date
Application number
BRPI0411112-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Wolfgang Glaesner
Yu Tian
Sheng-Hung Rainbow Tschang
Andrew Mark Vick
Rohn Lee Junior Millican
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0411112A publication Critical patent/BRPI0411112A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0411112-5A 2003-06-12 2004-06-10 proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga BRPI0411112A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47788003P 2003-06-12 2003-06-12
US57090804P 2004-05-13 2004-05-13
PCT/US2004/016611 WO2004110472A2 (en) 2003-06-12 2004-06-10 Fusion proteins

Publications (1)

Publication Number Publication Date
BRPI0411112A true BRPI0411112A (pt) 2006-07-18

Family

ID=33555478

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411112-5A BRPI0411112A (pt) 2003-06-12 2004-06-10 proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga

Country Status (17)

Country Link
US (1) US20070253966A1 (cg-RX-API-DMAC7.html)
EP (1) EP1641483B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007505643A (cg-RX-API-DMAC7.html)
CN (1) CN1802167A (cg-RX-API-DMAC7.html)
AT (1) ATE385806T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004247042A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0411112A (cg-RX-API-DMAC7.html)
CA (1) CA2526169A1 (cg-RX-API-DMAC7.html)
CY (1) CY1107248T1 (cg-RX-API-DMAC7.html)
DE (1) DE602004011770T2 (cg-RX-API-DMAC7.html)
DK (1) DK1641483T3 (cg-RX-API-DMAC7.html)
ES (1) ES2298785T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA05013564A (cg-RX-API-DMAC7.html)
PL (1) PL1641483T3 (cg-RX-API-DMAC7.html)
PT (1) PT1641483E (cg-RX-API-DMAC7.html)
SI (1) SI1641483T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004110472A2 (cg-RX-API-DMAC7.html)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US8093357B2 (en) 2002-03-01 2012-01-10 Xencor, Inc. Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
MXPA06006746A (es) * 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
DE602005016917D1 (de) 2004-05-13 2009-11-12 Lilly Co Eli Fgf-21-fusionsproteine
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
ATE482724T1 (de) * 2005-05-13 2010-10-15 Lilly Co Eli Pegylierte glp-1-verbindungen
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗ｃｄ３０抗体
EP2573111A1 (en) 2006-04-20 2013-03-27 Amgen Inc. GLP-1 compounds
SI1873166T1 (sl) * 2006-06-30 2011-01-31 Conaris Res Inst Ag IZBOLJĹ ANI sgp 130Fc DIMERJI
AU2007285976B2 (en) 2006-08-14 2011-08-18 Xencor, Inc Optimized antibodies that target CD19
US8394374B2 (en) 2006-09-18 2013-03-12 Xencor, Inc. Optimized antibodies that target HM1.24
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US12492253B1 (en) 2008-02-25 2025-12-09 Xencor, Inc. Anti-human C5 antibodies
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
UY38740A (es) 2009-05-05 2020-12-31 Amgen Inc Mutantes de fgf21 y usos del mismo
AU2010262927A1 (en) 2009-06-17 2012-01-19 Amgen Inc. Chimeric FGF19 polypeptides and uses thereof
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2010326024A1 (en) 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EP2359843A1 (en) 2010-01-21 2011-08-24 Sanofi Pharmaceutical composition for treating a metabolic syndrome
AU2011239689A1 (en) 2010-04-15 2012-11-08 Amgen Inc. Human FGF receptor and beta-Klotho binding proteins
EA201291482A1 (ru) 2010-07-09 2013-10-30 Байоджен Айдек Хемофилия Инк. Химерные факторы коагуляции
CA2815967A1 (en) * 2010-11-05 2012-05-10 Covx Technologies Ireland Limited Anti-diabetic compounds
HK1198173A1 (en) 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
JP4857396B1 (ja) * 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
RU2642310C2 (ru) 2011-06-28 2018-01-24 ИНХИБРКС ЭлЭлСи Слитые серпиновые полипептиды и способы их применения
US8951966B2 (en) 2011-07-01 2015-02-10 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
KR102132041B1 (ko) 2012-04-05 2020-07-09 에이씨 이뮨 에스.에이. 인간화된 타우 항체
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
WO2014085365A2 (en) 2012-11-28 2014-06-05 Ngm Biopharmaceuticals, Inc. Compositions and methods for treatment of metabolic disorders and diseases
DK2938740T3 (da) 2012-12-27 2022-06-20 Ngm Biopharmaceuticals Inc Kimære fgf19-peptider til anvendelse til behandling af galdesyrelidelser
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
WO2015065897A1 (en) 2013-10-28 2015-05-07 Ngm Biopharmaceuticals, Inc. Cancer models and associated methods
CN106662577B (zh) 2014-01-24 2020-07-21 恩格姆生物制药公司 结合蛋白及其使用方法
JP6712230B2 (ja) 2014-03-11 2020-06-17 ノバルティス アーゲー リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
WO2015183890A2 (en) 2014-05-28 2015-12-03 Ngm Biopharmaceuticals, Inc. Methods and compositions for the treatment of metabolic disorders and diseases
EP3674314B8 (en) 2014-06-10 2023-07-12 Amgen Inc. Apelin polypeptides
WO2015195509A2 (en) 2014-06-16 2015-12-23 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
TWI713453B (zh) * 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
WO2016065106A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
UY36370A (es) 2014-10-24 2016-04-29 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Polipéptidos fgf-21 modificados y sus usos
US10434144B2 (en) 2014-11-07 2019-10-08 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
US10800843B2 (en) 2015-07-29 2020-10-13 Ngm Biopharmaceuticals, Inc. Beta klotho-binding proteins
CN106397569B (zh) * 2015-08-01 2020-09-01 深圳红石科创生物科技发展有限公司 一种治疗代谢疾病的突变细胞因子融合蛋白
CN113201048B (zh) 2015-08-05 2022-10-04 陕西麦科奥特科技有限公司 有抗凝血和抗血小板活性的多靶点化合物及制法和用途
WO2017083276A1 (en) 2015-11-09 2017-05-18 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
CN107759696A (zh) 2016-08-19 2018-03-06 安源医药科技（上海）有限公司 人白介素7融合蛋白及其制备方法
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CA3034399A1 (en) 2016-08-26 2018-03-01 Ngm Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018166461A1 (en) * 2017-03-14 2018-09-20 Sunshine Lake Pharma Co., Ltd. Dual-target fusion proteins comprising the fc portion of an immunoglobulin
US11767520B2 (en) 2017-04-20 2023-09-26 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
JP2020533304A (ja) 2017-09-08 2020-11-19 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変型線維芽細胞成長因子２１（ｆｇｆ−２１）を用いる非アルコール性脂肪性肝炎（ｎａｓｈ）の処置方法
RS65720B1 (sr) 2017-12-22 2024-08-30 Novartis Ag Tretiranje metaboličkih poremećaja pomoću fgf21 varijanti
BR112020026512A2 (pt) 2018-07-03 2021-04-06 Bristol-Myers Squibb Company Formulações de fgf-21
CN109206523A (zh) * 2018-08-27 2019-01-15 沣潮医药科技（上海）有限公司 Tigit免疫粘附素、制备方法及用途
CN109748972B (zh) * 2019-01-31 2021-12-03 泉州师范学院 一种细胞珠蛋白-人源乳铁蛋白肽融合蛋白、基因及应用
CN115243725A (zh) 2020-01-08 2022-10-25 百时美施贵宝公司 Fgf-21缀合物配制品
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
EP4192495A1 (en) 2020-08-07 2023-06-14 Bristol-Myers Squibb Company Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis
US20240123031A1 (en) 2020-11-25 2024-04-18 Bristol-Myers Squibb Company Methods of treating liver diseases
EP4595977A1 (en) 2022-09-26 2025-08-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Ultra-long-acting platform comprising fc-advanced fatty acid chain
WO2024132147A1 (en) 2022-12-22 2024-06-27 Lifearc Galanin-2 receptor agonists
EP4642793A1 (en) * 2022-12-29 2025-11-05 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
HUT76369A (en) * 1994-07-29 1997-08-28 Smithkline Beecham Corp Novel soluble protein compounds
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
US6750334B1 (en) * 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
ATE406384T1 (de) * 2000-12-07 2008-09-15 Lilly Co Eli Glp-1 fusion proteine
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities

Also Published As

Publication number Publication date
AU2004247042A1 (en) 2004-12-23
ES2298785T3 (es) 2008-05-16
US20070253966A1 (en) 2007-11-01
DK1641483T3 (da) 2008-06-02
DE602004011770D1 (de) 2008-03-27
ATE385806T1 (de) 2008-03-15
EP1641483A2 (en) 2006-04-05
CN1802167A (zh) 2006-07-12
MXPA05013564A (es) 2006-03-09
JP2007505643A (ja) 2007-03-15
CY1107248T1 (el) 2012-11-21
PL1641483T3 (pl) 2008-07-31
DE602004011770T2 (de) 2009-02-05
EP1641483B1 (en) 2008-02-13
SI1641483T1 (sl) 2008-08-31
WO2004110472A3 (en) 2005-02-03
CA2526169A1 (en) 2004-12-23
PT1641483E (pt) 2008-04-29
WO2004110472A2 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
BRPI0411112A (pt) proteìna de fusão heteróloga, polinucleotìdeo, vetor, célula hospedeira, processo para produzir uma proteìna de fusão heteróloga, método para tratar um paciente, e, uso de proteìna de fusão heteróloga
UA130113C2 (uk) Мутеїн інтерлейкіну-21
AU2003215188A1 (en) Fusion proteins of humanized g250 specific antibodies and uses thereof
MX2008001865A (es) Proteinas de fusion de albumina.
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
WO2004009622A3 (en) Protein complexes of cellular networks underlying the development of cancer and other diseases
ATE443720T1 (de) Fc-interferon-beta fusionsproteine
WO2005077042A3 (en) Albumin fusion proteins
WO2002031134A3 (en) Novel serine protease genes related to dppiv
PL393646A1 (pl) Sposób wytwarzania polipeptydu
MY153718A (en) Formulation of human antibodies for treating tnf-(?) associated disorders
WO2003060071A3 (en) Albumin fusion proteins
HUP0203409A2 (hu) Gamma-interferon-konjugátumok
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
WO2003030821A3 (en) Albumin fusion proteins
DE60203692D1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
ATE514718T1 (de) Peptabody für krebsbehandlung
EP0369816A3 (en) Monoclonal antibodies specific for human polymorphic epithelial mucin
DK1636261T3 (da) Thrombopoietinproteiner med forbedrede egenskaber
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.